Results from the interim analysis of the phase II ZUMA-5 study, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, indicated that axicabtagene ciloleucel (axi-cel) demonstrated significant and durable clinical benefit in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
Though this particular study requires further follow-up, the investigators suggested that axi-cel may be a promising therapeutic approach for this patient population.
In an interview with CancerNetwork®, Caron A. Jacobson, MD, of the Dana-Farber Cancer Institute, explained the efficacy and safety findings observed in the interim analysis.
Transcription:
Yep. So, in total 125 patients with follicular lymphoma were in enrolled and treated, and 16 patients with marginal zone lymphoma were enrolled and treated. The way this study was designed is that the…
